Ian Flinn, MD: Both the CD20 and CD19 antibodies—mosunetuzumab, I think we’ve been working with that, I think that’s an impressive antibody. That tolerability of mosunetuzumab is actually pretty good. We’ve worked in the past with a CD19 bispecific frankly, and it was worse than CAR [chimeric antigen receptor] T cells. And so, I don’t know whether that was specifically that product in and of itself, but because the CAR T cells were targeting CD19 and this one was targeting CD19 and still using an IMiD [immunomodulatory imide drug]therapy, we saw a lot of adverse events and ultimately, that trial had to be stopped.
So clearly, not just a CD19 in and of itself, we don’t see that with MOR208, a novel Fc-enhanced CD19-targeted antibody]. It’s an immunotherapy for some reason that seems to be causing that problem. But as a class, I’m very bullish on bispecifics. I think there’s a great deal of excitement with that group of antibodies. We’re testing several in our program.
John Pagel, MD, PhD: Yeah, and I’ll just say I’m bullish on them as well. I’m bullish on tafasitamab, too because that agent, these bispecifics are off the shelf, right? We can get them to patients right away. It’s not something we can do with the CAR T-cell treatment as we discussed early on in the program.
Ian Flinn, MD: Yeah, I think 1 of the very important parts here is that you can give it quickly to people with a good tolerability. That’s true with both MOR208 as well as some of the new bispecifics that are coming around. Go ahead John.
John Pagel, MD, PhD: And of course, don’t forget, I’m sorry to interrupt you there, but I do think it’s important that we have to remember that the bispecifics, which you’ve been alluding to, also have significant toxicity and can have CY10 release and other toxicities like we see with CAR T-cell treatment. And again, we’re not seeing that with the tafasitamab or the MOR208. So, bispecifics are encouraging. I’m bullish on them as we said. They’re off the shelf. But they are potentially very toxic in some patients.
Have you used blinatumomab in patients with large-cell lymphoma? It’s indicated in ALL [acute lymphoblastic leukemia]. It had some of the same toxicities that we’ve been talking about,
neurotoxicity and so forth. But I haven’t really used it in patients with large-cell lymphoma. It’s very cumbersome to give.
Yeah, I think that’s the problem, right? It’s hard to deliver, and the toxicity of that drug can be very significant. These people have to be in the hospital for a significant amount of time, not uncommonly. And the activity is not great, so I’m not a large user. In fact, we are really almost never using that in this space. We have other drugs now, as we’ve been talking about.
Transcript edited for clarity.
Challenges for Non–CAR T-Cell Treatment of Early Relapsed DLBCL
April 18th 2024During a Case-Based Roundtable® event, Elizabeth A. Brém, MD, discussed treatment approaches for a patient with early relapsed or primary refractory diffuse large B-cell lymphoma in the first article of a 2-part series.
Read More
Glofitamab Plus Chemo Improves Survival vs Rituximab in R/R DLBCL
April 16th 2024The phase 3 STARGLO trial met its primary end point, improving overall survival in patients with relapsed/refractory diffuse large B-cell lymphoma with glofitamab and chemotherapy vs rituximab and chemotherapy.
Read More
Comparing Results with Loncastuximab in the Clinic and Real-World Settings in DLBCL
April 1st 2024During a Case-Based Roundtable® event, Emily Ayers, MD, discussed the long-term results with loncastuximab in patients with diffuse large B-cell lymphoma and how this drug fared in the real-world setting in the second article of a 2-part series.
Read More
Fitting Loncastuximab Into the Current Landscape of R/R DLBCL
March 21st 2024During a Case-Based Roundtable® event, Emily Ayers, MD, discussed the current landscape for the treatment of patients with diffuse large B-cell lymphoma, the need for better risk stratification data, and what led to the approval of loncastuximab tesirine in the first article of a 2-part series.
Read More